Oncolytics Biotech Inc. (ONC.TO)


Toronto - Toronto Delayed Price. Currency in CAD
0.34-0.00 (-1.47%)
At close: 3:59 PM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.33
Prev Close0.34
Bid0.32 x
Ask0.35 x
Day's Range0.32 - 0.34
52wk Range0.31 - 0.90
1y Target EstN/A
Market Cap40.36M
P/E Ratio (ttm)-3.07
Beta2.86
Volume84,351
Avg Vol (3m)87,456
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • CNW Group23 hours ago

    Media Advisory - Oncolytics Biotech® Inc. Announces Participation in the 4th Annual Immuno-Oncology Summit

    Media Advisory - Oncolytics Biotech® Inc. Announces Participation in the 4th Annual Immuno-Oncology Summit

  • PR Newswire23 hours ago

    Media Advisory - Oncolytics Biotech® Inc. Announces Participation in the 4th Annual Immuno-Oncology Summit

    CALGARY, Aug. 30, 2016 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (ONC.TO) (ONCYF) (ONY.F), will present at the 4th Annual Immuno-Oncology Summit in a session today, Tuesday, August 30th. The summit takes place from August 29th to September 2nd in Boston, MA. Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.  Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

  • PR Newswire21 days ago

    MEDIA ADVISORY - Oncolytics Biotech® Inc. Announces Participation in the Canaccord Genuity 36th Annual Growth Conference

    CALGARY, Aug. 10, 2016 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (ONC.TO) (ONCYF) (ONY.F), will present at the 36th Annual Canaccord Genuity Growth Conference in a session on Thursday, August 11th, 2016 at 11:00 a.m. ET. The conference takes place on August 10th and 11th in Boston, MA. Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.  Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.